Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plexin B2 Expression in Psoriasis: NB-UVB, Acitretin, and Combined Therapy
NCT05184348Phase 1Completed
- Sponsor
- South Valley University
- Start
- Sep 2021
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of acitretin in Psoriasis vulgaris (PV) (4 arms), sponsored by South Valley University. Primary endpoints: Improve the prognosis of patients with psoriasis Vulgaris at 3 months and Level of Plexin B2 and genetic mutation at 3 months. Started Sep 2021; status: completed.
02
Drugs
acitretin
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT05184348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05184348.